Advertisement

Topics

Lyndra, Inc. and Allergan Sign a Partnership to Develop Ultra-Long-Acting Oral Products

20:31 EDT 9 Sep 2017 | Biotech-Finances

Thursday, September 7th 2017 at 11:00am UTC Companies will collaborate to create products dosed once-weekly for the treatment of Alzheimer’s disease. WATERTOWN, Mass.–(BUSINESS WIRE)– Lyndra, Inc. (Lyndra) announced today a partnership with Allergan plc to develop orally administered ultra-long-acting (once-weekly) products for the treatment of Alzheimer’s disease. The basis of the collaboration between the Boston-based …

Cet article Lyndra, Inc. and Allergan Sign a Partnership to Develop
Ultra-Long-Acting Oral Products
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Lyndra, Inc. and Allergan Sign a Partnership to Develop Ultra-Long-Acting Oral Products

NEXT ARTICLE

More From BioPortfolio on "Lyndra, Inc. and Allergan Sign a Partnership to Develop Ultra-Long-Acting Oral Products"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...